Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00792688 · ClinicalTrials.gov registry record · Phase 2

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

A Phase 2 study of Wounds, sponsored by TR Therapeutics.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target
1
Study location

NCT00792688 is a Phase 2 study of Wounds that has completed, run by TR Therapeutics. The registered enrollment target is 26 participants, below the 99-participant average among 6 other Wounds trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00792688, a Phase 2 study of Wounds, has completed, sponsored by TR Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

Conditions Studied

Interventions

  • DRUG GLYC-101 Gel (0.1%)
  • DRUG GLYC-101 Gel (1.0%)
  • DRUG GLYC-101 Placebo

Study Locations (1)

California

  • CLINICAL TESTING CENTER of BEVERLY HILLS - Beverly Hills

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2008-10
Est. Completion 2010-01
Phase Phase 2

Sponsor

TR Therapeutics

4 total trials

What the Registry Record Tells You About NCT00792688

The ClinicalTrials.gov registry entry for NCT00792688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 6 other Wounds trials with a reported enrollment target (74% lower). The listed sponsor is TR Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Wounds appearing as the primary indexed condition, and to 3 interventions - of which GLYC-101 Gel (0.1%) is the first listed.

NCT00792688 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00792688 about?

NCT00792688 is a clinical study titled "Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation". The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will obs...

What is the current status of trial NCT00792688?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-10. Estimated completion is 2010-01.

What conditions does trial NCT00792688 study?

This clinical trial studies the following conditions: Wounds.

What interventions are being tested in trial NCT00792688?

The interventions under investigation include: GLYC-101 Gel (0.1%) (DRUG), GLYC-101 Gel (1.0%) (DRUG), GLYC-101 Placebo (DRUG).

Who is sponsoring clinical trial NCT00792688?

This trial is sponsored by TR Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00792688 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wounds

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.